Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

December 23, 2024

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

October 02, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.